NS Partners Ltd bought a new position in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 2,700 shares of the company’s stock, valued at approximately $206,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Bessemer Group Inc. increased its position in Merck & Co., Inc. by 973.1% in the fourth quarter. Bessemer Group Inc. now owns 770,416 shares of the company’s stock worth $58,866,000 after buying an additional 698,622 shares during the period. Nomura Asset Management Co. Ltd. increased its position in Merck & Co., Inc. by 20.4% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 1,837,508 shares of the company’s stock worth $140,403,000 after buying an additional 311,732 shares during the period. Resources Investment Advisors Inc. increased its position in Merck & Co., Inc. by 41.4% in the fourth quarter. Resources Investment Advisors Inc. now owns 11,717 shares of the company’s stock worth $895,000 after buying an additional 3,430 shares during the period. King Luther Capital Management Corp increased its position in Merck & Co., Inc. by 1.3% in the fourth quarter. King Luther Capital Management Corp now owns 1,719,835 shares of the company’s stock worth $131,413,000 after buying an additional 22,395 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter worth $1,176,000. 73.85% of the stock is currently owned by hedge funds and other institutional investors.
In other news, major shareholder Merck & Co., Inc. bought 4,121,683 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average price of $16.00 per share, with a total value of $65,946,928.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kenneth C. Frazier sold 92,913 shares of the firm’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $80.03, for a total value of $7,435,827.39. Following the transaction, the chief executive officer now directly owns 784,863 shares of the company’s stock, valued at approximately $62,812,585.89. The disclosure for this sale can be found here. Insiders have sold 766,625 shares of company stock valued at $62,212,275 in the last ninety days. Company insiders own 0.27% of the company’s stock.
Shares of MRK opened at $77.55 on Thursday. Merck & Co., Inc. has a one year low of $57.49 and a one year high of $83.85. The firm has a market cap of $207.80 billion, a PE ratio of 17.87, a price-to-earnings-growth ratio of 1.83 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 0.82.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, April 30th. The company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.17. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The business had revenue of $10.82 billion during the quarter, compared to analysts’ expectations of $10.45 billion. During the same quarter last year, the business posted $1.05 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Sell-side analysts anticipate that Merck & Co., Inc. will post 4.72 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/16/ns-partners-ltd-buys-shares-of-2700-merck-co-inc-mrk.html.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Recommended Story: Why are percentage gainers important?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.